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Abstract: There is ongoing interest in optimizing basal insulin treatment by developing insulins 
with a flat pharmacological profile, a long duration of action (typically beyond 24 hours) and 
minimum day-to-day variation. Glargine-300 is a modified form of the long-acting insulin 
analog glargine in that it has been concentrated at 300 units/mL rather than the conventional 
100 units/mL. Glargine-300 has a longer duration of action and a flatter pharmacological profile 
than original glargine-100. This property allows for more flexibility around the timing of admin-
istration, when injected once per day. Open-label studies in patients with diabetes have shown 
that treatment with glargine-300 achieves comparable glycemic control compared to treatment 
with glargine-100, albeit with consistently higher insulin requirements. These studies also showed 
that treatment with glargine-300 was associated with lower risks of nocturnal hypoglycemia in 
patients with type 2 diabetes, particularly those already on insulin, whereas data are mixed in 
insulin-naïve patients with type 2 diabetes or in patients with type 1 diabetes. Treatment with 
glargine-300 did not appear to affect the risk of overall hypoglycemia, whereas studies lacked 
sufficient power to investigate the effect on the risk of severe hypoglycemia. Future studies 
need to establish the role of glargine-300 in the treatment of diabetes alongside the other new 
long-acting insulin analog, insulin degludec, which was recently introduced to the market.
Keywords: insulin glargine-300, type 1 diabetes, type 2 diabetes, hypoglycemia, HbA1c, 
patient-reported outcomes
Introduction
Diabetes is a rapidly increasing global health problem. As of 2015, the World Health 
Organization (WHO) has estimated that over 415 million adults have been diagnosed 
with diabetes, a number expected to have risen by more than 50% by 2040.1 In the 
US, about a third of people with diabetes are treated with insulin.2 The number of 
patients requiring insulin is expected to rise more steeply. Factors contributing to 
this rise include longer life expectancy for people with diabetes,3 the aging of the 
population as a whole,4 the younger age at which both type 1 and type 2 diabetes are 
being diagnosed,5,6 better resource facilities for low- and middle-income countries7 
and the continuation of the obesity epidemic that tends to start at younger ages.8
Basal, ie so-called long-acting, insulin agents form the backbone of most therapeutic 
insulin regimens. Indeed, the majority of patients with type 1 diabetes are treated with 
basal-bolus insulin injection regimens consisting of a once- or twice-daily long-acting 
insulin agent in combination with a rapid-acting insulin (analog) given prior to meals. 
For people with type 2 diabetes, most guidelines recommend to add basal insulin 
when glycemic control can no longer be maintained with alternative (usually oral) 
glucose-lowering treatment(s) alone,9,10 particularly in patients with impaired fasting 
glucose levels. Parenthetically, it should be acknowledged that the terms “long-acting” 
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or “rapid-acting” are factually misused, as all insulins have 
the same duration of action once in their free form in the 
circulation. Thus, the term “long-acting” for particular insulin 
products refers to the protracted uptake of these insulins from 
the subcutaneous depot into the circulation or their binding 
to albumin from which the insulin is slowly freed.
Of the long-acting insulin agents currently available, 
neutral protamine Hagedorn (NPH) insulin is the insulin that 
is around for the longest time. Some now call this insulin 
intermediate-acting, because its duration of action rarely 
exceeds 14 hours.11 At the turn of the century, the insulin 
analogs glargine and detemir were marketed as alternatives 
to NPH insulin, as they exhibited longer duration of action 
that would typically provide 24-hour coverage. The duration 
of action is slightly longer for glargine than for detemir, 
although large inter-individual differences exist.11,12 Glargine 
has less of a peak than either NPH insulin or detemir, 
although the assertion that it had no peak at all was flawed 
from the start.13 Detemir, on the other hand, was claimed to 
have a more predictable glucose-lowering action than either 
NPH insulin or glargine.13 Both of these features have been 
hypothesized to explain why the use of these long-acting 
insulin analogs may be associated with reduced risks of 
(particularly) nocturnal hypoglycemia when compared to 
NPH insulin.14 Combining rapid-acting analogs before meals 
with a long-acting insulin analog before bedtime has become 
the default insulin treatment for patients on multi-injection 
basal-bolus insulin regimens, particularly those with type 
1 diabetes.
Nevertheless, current insulin regimens are still far from 
being perfect. Iatrogenic hypoglycemia remains the bar-
rier for optimal glucose control for both type 1 and type 2 
diabetes patients on insulin,15 a problem that long-acting 
insulin analogs have failed to alleviate. Insulin analogs with 
longer duration of action, flatter profiles, and less intra- and 
inter-individual variations are urgently needed to allow 
for better glucose control at lower risk of hypoglycemia. 
Glargine-300 is a “new” long-acting insulin analog, recently 
approved by both the US Food and Drug Administration 
and European Medicines Evaluation Agency for marketing 
in the US and Europe, respectively. Glargine-300 is a 
three times more concentrated formulation of “traditional” 
glargine, ie, 300 units/mL versus 100 units/mL. In this 
review, I will summarize available evidence regarding 
the efficacy of glargine-300 with respect to important 
patient outcomes, including glycemic control (as reflected 
by glycated hemoglobin [HbA1c]), hypoglycemia and 
quality of life.
Pharmacokinetics and 
pharmacodynamics of glargine-100 
and glargine-300
NPH insulin consists of a complex of insulin, zinc and the 
fish protein protamine, in which the latter component reduces 
the solubility of NPH within the subcutaneous area, thus 
delaying its absorption into the circulation. However, the 
insulin molecule itself is structurally unaltered.16 A limitation 
of NPH insulin is its need for resuspension before injection, 
thus contributing to large variation in glucose-lowering 
effects.17 Glargine has a modified molecular structure in 
that two arginine residues are added to the C-terminus of 
the B-chain and glycine replaces asparagine at position 21 
of the A-chain of the insulin molecule. These alterations 
result in the shifting of isoelectric point to a lower pH, 
which reduces its solubility at the physiologic pH of the 
injection site.18 Glargine is therefore kept as an acidic solu-
tion, quickly forming microprecipitates after injection in the 
neutral environment of subcutaneous tissue. The insulin then 
slowly dissipates from these microprecipitates, allowing it 
to be absorbed into the circulation.19
The microprecipitates explain the more gradual appear-
ance of insulin in the circulation and hence its flatter insulin 
profile than NPH, although as said earlier, it is not completely 
peakless. Glargine has an onset of action of 3–4 hours and a 
half-life of 12–14 hours for clinically relevant doses with a 
duration of glucose-lowering action of ~24 hours.17 Dosing 
once a day is usually sufficient, except when very low doses 
are being used, such as in young children and extremely 
insulin-sensitive adults with type 1 diabetes.
The molecular structure of glargine-300 is not different 
from that of glargine in the usual 100 units/mL concentra-
tion. Nevertheless, glargine-300 has a flatter pharmacokinetic 
and pharmacodynamic profile than the original formulation, 
with slower onset of action and an extended duration of 
glucose-lowering action by at least several hours.20 The rea-
son for the differences in pharmacological efficacy between 
glargine-300 and original glargine has not been entirely clari-
fied, but the surface dependency of insulin release from the 
precipitates has been suggested as a potential explanation.21 
It is also possible that more condensed formulation gives 
it greater structural strength and relative resistance against 
degradation. Remarkably, however, despite its longer dura-
tion of action, biological availability is ~10% lower.20 This 
observation suggests that some amount of glargine-300 
does not form microprecipitates or that longer presence in 
the subcutaneous area somehow enhances its degradation, 
although this remains speculative.
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Clinical studies
The clinical efficacy and safety of treatment with glargine-
300 have been examined in people with type 1 and type 2 
diabetes in various trials of the so-called EDITION program 
and in one study using continuous glucose monitoring 
(CGM, Table 1).22–27 All trials were open-label, report-
edly because of the different pen systems used to inject 
glargine-300 or glargine-100, which may have introduced 
bias. The primary end point of all EDITION trials was the 
change in HbA1c levels from baseline to end of treatment, 
but a strict treat-to-target protocol of weekly insulin dose 
adjustments was used to obtain fasting glucose levels of 
4.4–7.2 mmol/L in type 1 and of 4.4–5.6 mmol/L in type 2 
diabetes. As a consequence, differences in the end-of-study 
HbA1c levels between the active compound and compara-
tor (ie, glargine-100) study arms were kept to a minimum, 
yet these protocols provided little guidance with respect to 
avoiding hypoglycemia.
Hypoglycemia, severe, nocturnal or any, was the most 
important secondary end point for these trials. The term 
“any hypoglycemia” was used for all events reported as 
hypoglycemia, whether accompanied by symptoms or not 
or confirmed with a self-measured glucose value or not. 
Confirmed hypoglycemia was defined as a documented 
glucose value at or below 3.9 mmol/L, with or without 
symptoms, and severe hypoglycemia as an event requiring 
assistance from another person for treatment. Hypoglycemic 
events with a cutoff at 3.0 mmol/L were analyzed separately. 
Instructions with respect to performing self-measured plasma 
glucose (SMPG) by finger stick differed from one study to 
an other, depending on the intensity of insulin treatment, 
but were similar between the study arms. As a consequence, 
comparing rates of hypoglycemia between studies can only 
be done with great caution. Another cautionary note is that 
SMPG frequency was not recorded; since all studies were 
open-label, the rate at which SMPG was performed may not 
necessarily be balanced between the study arms, although the 
direction of such potential bias remains unclear.
Sanofi Aventis was the sponsor of the EDITION trial 
program and was actively involved in trial design, data col-
lection, management and interpretation, statistical analysis, 
and writing of the manuscripts.
Type 1 diabetes
EDITION4 and EDITIONJP1 were phase III studies con-
ducted in patients with type 1 diabetes, the latter exclusively 
in Japanese patients, comprising 549 and 243 participants, 
respectively.25,26 In both studies, the vast majority of patients 
used glargine-100 at baseline and only a small minority 
injected basal insulin twice daily. Patients were randomized 
1:1 to either glargine-300 or glargine-100 and were instructed 
to adjust the dose of glargine-300 by 1.5–4.5 units and that 
of glargine-100 by 1.0–4.0 units to achieve the beforemen-
tioned fasting glucose target. In EDITION4, half of the study 
population was instructed to inject the basal insulin in the 
evening (between evening meal and bedtime), and the other 
half was instructed to inject in the morning (ie, between 
prebreakfast and lunch).
Table 1 Overview of randomized controlled trials on glargine-300
Trial name or first 
author, year
Population Countries Number of 
participants
Study duration Primary 
outcome 
eDiTiON 1,22 2014 T2DM on basal and 
mealtime insulin
Canada, Czech Republic, estonia, Finland, 
France, Germany, Hungary, Latvia, 
Mexico, the Netherlands, Romania, 
Russia, South Africa, and the USA
807 6 months (and 
6-month extension)
Change in HbA1c
eDiTiON 2,23 2014 T2DM on basal insulin Canada, Chile, Finland, France, Germany,
Hungary, Mexico, Portugal, Romania,
Russia, South Africa, Spain, and the USA
811 6 months (and 
6-month extension)
Change in HbA1c
eDiTiON 3,24 2015 T2DM on oral agents 
(insulin-naïve)
Canada, USA, europe (12 countries) 878 6 months Change in HbA1c
eDiTiON 4,25 2015 T1DM Canada, Czech Republic, Denmark, 
estonia, Finland, Hungary, Japan, Latvia, 
the Netherlands, Romania, Sweden, and 
the USA
549 6 months Change in HbA1c
eDiTiON JP1,26 2016 T1DM Japan 243 6 months Change in HbA1c
eDiTiON JP2,27 2016 T2DM on basal insulin Japan 241 6 months Change in HbA1c
Jinnouchi et al,28 
2015
T1DM Japan 20 (cross-over) 28 days 24 hours glucose 
variability by CGM
Abbreviations: CGM, continuous glucose monitoring; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; HbA1c, glycated hemoglobin.
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In both studies, HbA1c levels decreased to a similar 
extent in both randomized groups, with the upper bound 
of the mean differences between the two treatments being 
within the prespecified margin of 0.4% (4.4 mmol/mol), 
indicating non-inferiority of glargine-300 in comparison to 
glargine-100 (Figure 1). There were no differences between 
morning and evening injectors. A small-scale study that 
compared the effect of 4 weeks of glargine-300 with that 
of glargine-100 in 20 people with type 1 diabetes using 
a cross-over design reported no differences between the 
two treatments on glucose variability measured by 3-day 
CGM recordings.28 In all studies, patients randomized to 
glargine-300 on average increased their basal insulin doses 
more than patients randomized to comparator treatment, the 
difference ranging from 12% to .20%, with mealtime insulin 
doses remaining largely unchanged.
More than 90% of patients examined in the EDITION 
studies reported hypoglycemia, many of which were con-
firmed by glucose measurements and most were recorded 
during daytime. In EDITIONJP1, glargine-300 was associ-
ated with 20% and 34% lower relative risks for any confirmed 
or severe hypoglycemia and for such events during the night 
(0:00–05:59 hours, Table 2), respectively.26 However, these 
lower risks were mainly driven by risk reductions observed 
in the first 8 weeks, when insulin was titrated. In EDITION4, 
glargine-300 reduced the rate of nocturnal hypoglycemic 
episodes by 31% during the first 8 weeks, but had no risk-
reducing effect beyond that time point, so that the risk 
reduction over the full 6-month period was a nonsignificant 
10% (Table 2). There were no differences in the risk of 
documented hypoglycemia at any time of the day between 
the two treatments, irrespective of whether such an event was 
defined by a glucose value #3.9 mmol/L or ,3.0 mmol/L.25 
Severe hypoglycemia occurred numerically more often in 
patients randomized to glargine-100 than in those random-
ized to glargine-300, but such events were too uncommon to 
analyze statistically with sufficient accuracy. In both trials, 
the increase in body weight was somewhat less in patients 
assigned glargine-300 than in those assigned glargine-100. 
There were no differences in injection site reactions or other 
treatment-related adverse events between glargine-300 and 
glargine-100.
Type 2 diabetes
Four published phase III EDITION studies have thus far 
been conducted in patients with type 2 diabetes: EDITION1 
in patients on basal-bolus insulin regimens (n=807),22 
EDITION2 in patients on oral agents and basal insulin only 
(n=811),23 EDITION3 in insulin-naïve patients failing on oral 
agents (n=878)24 and EDITIONJP2 in Japanese patients on 
basal insulin (with/without oral agents, n=241).27 As in the 
trials involving patients with type 1 diabetes, all studies were 
conducted for a duration of 6 months, were multicenter and 
multinational (except in the Japanese trial), had an open-label 
study design and randomized patients 1:1 to either glargine-
300 or glargine-100 once daily, to be administered in the 
evening. The protocols for achieving the fasting plasma 
glucose target had the minimal insulin dose adjustment set at 
3.0 units, except in the Japanese trial where this was 1.5 units 
for glargine-300 and 1.0 unit for glargine-100.27 
In the four studies conducted in people with type 2 
diabetes, glargine-300 was as effective as glargine-100 
in lowering HbA1c levels (Figure 1) and in increasing 
the proportion of patients achieving glycemic targets 
(ie, HbA1c ,53 mmol/mol [7%]). In neither study did the 
upper confidence limit of the mean difference between the 
two treatments exceed the 4.4 mmol/mol (0.4%) margin, 
thus establishing non-inferiority of glargine-300. There were 
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Figure 1 effect of treatment with glargine-300 (blue bars) as compared to glargine-100 (green bars) on the change in HbA1c levels in 6-month eDiTiON trials in people with 
type 1 diabetes (eDiTiON 4 and JP1) or type 2 diabetes (eDiTiON 1, 2, 3 and JP2).22–27
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similar reductions in fasting plasma glucose, self-measured 
pre-meal glucose values and in 7- or 8-point self-measured 
glucose profiles (performed only in patients on basal-bolus 
insulin regimens) across the two randomized treatments. In 
general, the doses of glargine-300 and of glargine-100 were 
gradually increased in all patients, but more so in patients ran-
domized to glargine-300, who ended with about 10%–17% 
greater basal insulin doses than those randomized to 
glargine-100. In EDITION 1, mealtime insulin use remained 
unchanged from baseline to end of follow-up and did not 
differ between glargine-300 and glargine-100 users.22
As expected, hypoglycemia was reported less frequently 
by patients with type 2 diabetes than those with type 1 dia-
betes and depended on the insulin treatment regimen, ie, the 
frequency was highest in patients on basal-bolus insulin 
regimens (EDITION 1) and lowest in insulin-naïve patients 
who started basal insulin alone (EDITION 3). Across studies, 
confirmed (ie, documented by self-measurement) nocturnal 
or severe nocturnal hypoglycemia occurred less frequently 
and among fewer people in the glargine-300 study arm than 
in the glargine-100 study arm. In EDITION 1–3 studies, 
6 months of treatment with glargine-300 reduced the popula-
tion at risk for nocturnal hypoglycemia by 22%–37%. The 
rate of such events was reduced by about a third in patients 
already on insulin, but was not affected in insulin-naïve 
patients with type 2 diabetes (Table 2). Although most of 
the difference in risk for nocturnal hypoglycemia between 
glargine-300 and glargine-100 occurred in the first 8 weeks 
after randomization, it generally persisted for the remainder 
of the 6-month treatment period. For any confirmed or severe 
hypoglycemia, ignoring the first 8 weeks, the treatments 
resulted in mild (ie, ~10%) risk reductions that often failed 
to reach statistical significance. In EDITION JP2, the curves 
describing cumulative event rates for confirmed or severe 
nocturnal hypoglycemia over time started to diverge after 
8 weeks of treatment with rates progressing about 50% slower 
in patients assigned glargine-300 compared to those assigned 
glargine-100.27 Severe hypoglycemia was so infrequent that 
it could not be analyzed. Two studies reported that use of 
glargine-300 caused 0.5 and 1.0 kg lower weight gain than 
Table 2 Nocturnal hypoglycemia in studies on glargine-300
Study, number of participants Glargine-300 Glargine-100 Relative risk or 
rate ratio (95% CI)
Type 1 diabetes
eDiTiON 4, n=54925
– No of participants (%)
– No of events (per participant-year)
188 (68.6)
ND (8.0)
193 (70.2)
ND (9.0)
0.98 (0.88–1.09)
0.90 (0.71–1.14)
eDiTiON JP1, n=24326
– No of participants (%)
– events (per participant-year)
84 (68.9)
444 (7.46)
98 (81.0)
663 (11.24)
0.85 (0.73–0.99)
0.66 (0.48–0.92)
Jinnouchi et al, n=20 (cross-over)28
– No of participants (%)
– No of events (per participant-year)
4 (20.0)
6 (3.6)
8 (40.0)
20 (12.0)
0.50 (0.18–1.40)*
0.30 (0.11–0.72)*
Type 2 diabetes
eDiTiON 1, n=807
(basal-bolus)22
– No of participants (%)
– No of events (per participant-year)
180 (44.6)
610 (3.13)
231 (57.5)
813 (4.20)
0.78 (0.68–0.89)
0.75 (0.58–0.95)
eDiTiON 2, n=811
(basal insulin)23
– No of participants (%)
– No of events (per participant-year)
114 (28.3)
362 (1.89)
162 (39.9)
713 (3.68)
0.71 (0.58–0.86)
0.52 (0.35–0.77)*
eDiTiON 3, n=878
(insulin-naïve)24
– No of participants (%)
– No of events (per participant-year)
78 (17.9)
263 (1.31)
103 (23.5)
265 (1.34)
0.76 (0.59–0.99)
0.98 (0.64–1.48)
eDiTiON JP2, n=241  
(basal insulin)27
– No of participants (%)
– No of events (per participant-year)
34 (28.3)
129 (2.18)
55 (45.8)
297 (4.98)
0.62 (0.44–0.88)
0.45 (0.21–0.96)
Note: *Calculated on data provided in the paper.
Abbreviations: ND, no data; CI, confidence interval; No, number.
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use of glargine-100, respectively,23,27 but this weight benefit 
was not achieved in two other studies.22,24 Other adverse 
effects occurred at similar frequency in the glargine-300 and 
glargine-100 treatment arms.
Both EDITION1 and EDITION2 trials had a predefined 
extension period of another 6 months, during which 
participants were maintained on their assigned treatment.29,30 
These extensions more or less confirmed the findings that 
were initially reported. Thus, glycemic control, as reflected 
by changes in HbA1c level, fasting glucose and self-measured 
glucose profiles, remained largely comparable between the 
two treatment arms from study start until the end of the exten-
sion period. The rate of confirmed nocturnal hypoglycemia 
remained 16%–37% lower in patients on glargine-300 com-
pared to those on glargine-100, but the 6-month extension 
period did not appear to contribute to this difference. The 
annualized event rate of any confirmed hypoglycemia was 
not different between the two treatment arms in either of the 
two extension trials.
Meta-analyses
A prespecified meta-analysis of the first three EDITION trials 
showed 15% and 38% lower risks of any, and nocturnal, 
confirmed hypoglycemia (glucose #3.9 mmol/L), respec-
tively, in patients with type 2 diabetes assigned glargine-300 
as compared to those assigned glargine-100. The analysis 
revealed no differences with respect to HbA1c, fasting 
plasma glucose or self-measured glucose profiles.31 Network 
meta-analyses, also called mixed treatment comparisons, 
simultaneously pool data from both direct comparisons 
within randomized trials and indirect comparisons across 
trials with a common comparator (eg, placebo), to compare 
multiple (ie, three or more) treatment options.32 Such an 
analysis thus allows an estimation of comparative effects 
of interventions for which direct head-to-head comparisons 
are not yet available. In a recent network meta-analysis, 
41 studies were included to compare the efficacy and safety of 
glargine-300 with various other basal insulins and with pre-
mixed insulin in patients with type 2 diabetes.33 The analysis 
focused on patients treated with basal insulin in conjunction 
with oral therapy, but not requiring meal-time insulin, for 
which 25 studies were found. This analysis revealed that 
glycemic control was comparable between glargine-300 
and insulin detemir, NPH, degludec and premixed insulin. 
Glargine-300 was associated with a lower rate of nocturnal 
hypoglycemia (glucose ,3.9 mmol/L) compared to the 
other insulin products, although this difference did not reach 
statistical significance for degludec and detemir.
Patient-reported outcomes
Most EDITION studies examined the effect of glargine-300 
on treatment satisfaction and quality of life, as measured by 
the validated Diabetes Treatment Satisfaction Questionnaire 
(DTSQ) and EuroQol 5 Dimensions (EQ-5D) questionnaire, 
respectively. In EDITION1, treatment satisfaction increased 
somewhat more in patients randomized to glargine-300 
than in those randomized to glargine-100.22 However, 
this improvement appeared unrelated to the frequency of 
perceived hypoglycemia, and the difference was no longer 
observed at the end of the 6-month extension period.29 
Treatment satisfaction did not differ between randomized 
groups in the other three studies investigating this outcome. 
The two treatments also showed no differences with respect 
to perceived quality of life or fear of hypoglycemia. However, 
fear of hypoglycemia was assessed only in insulin-naïve 
patients with type 2 diabetes starting insulin and in patients 
with type 1 diabetes who had low baseline scores on the 
hypoglycemia-fear questionnaire.24,25
Glargine-300 in clinical context
The studies conducted thus far showed that glargine-300 was 
about as efficacious as glargine-100 and – by inference – 
other basal insulins in lowering HbA1c or in achieving 
targets for glycemic control. On a unit-by-unit comparison, 
the glucose-lowering effect of glargine-300 was ~20% lower 
than glargine-100, as reflected by the higher insulin doses 
required to obtain similar glycemic control at the end of 
follow-up. Some studies reported somewhat less weight gain 
in patients treated with glargine-300 than in those treated 
with conventional glargine. In patients with type 2 diabetes, 
treatment with glargine-300 was associated with about 25% 
lower rates of nocturnal hypoglycemia than treatment with 
glargine-100. This effect was also observed in patients with 
type 1 diabetes, but appeared to be limited largely to the first 
8 weeks of treatment and not, or to much lesser extent, beyond 
that period. Severe hypoglycemia, defined as those events 
requiring assistance from another person, was so infrequent 
that it could not be analyzed with sufficient accuracy in any 
of the studies or in the meta-analyses.
A ~25% reduction in nocturnal hypoglycemia may seem 
trivial, because most hypoglycemic events occur during day-
time (which were not affected by glargine-300 treatment) and 
because evidence is missing that this effect is mirrored by a 
similar reduction in severe hypoglycemia that is regarded as 
clinically more meaningful. However, many patients and their 
partners view nocturnal hypoglycemia as deeply disturbing 
and of more concern than events that occur during daytime.34 
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Nocturnal hypoglycemia causes loss of several hours of sleep 
when patients are awakened and retains a negative impact 
on sleep quality,35 even when patients do not awake.36 The 
majority of patients are fatigued and have a reduced function-
ing capacity the day following a nocturnal event, and many 
report taking or requiring a nap.36 Twenty to 30% of patients 
skip a day at the office or are unable to fulfill their tasks, thus 
falling behind in work productivity.37 Approximately 25% of 
patients contact their health care provider and 15% reduce 
their insulin doses.36 Finally, 50% of partners are also awak-
ened by a nocturnal hypoglycemia in their spouse.35
Although the lower incidence of nocturnal hypoglycemia 
associated with glargine-300 was fairly consistent across 
studies, there are some potential flaws with the design of 
the EDITION studies that need to be discussed to assess the 
clinical relevance of this observation. First, one may ques-
tion the definition of hypoglycemia as any SMPG value at 
or below 3.9 mmol/L. Although this was based on a recent 
consensus report from the American Diabetes Association,38 
the report argued that this single threshold value, chosen 
mainly for pragmatic reasons, should be used as an alert 
value for people on medication known to cause hypoglycemia 
rather than as a strict separation between normal and below-
normal glucose values, a vision that was recently reiterated 
by another expert group.39 Indeed, although plasma glucose 
levels #3.9 mmol/L usually elicit a counterregulatory 
hormone response in nondiabetic individuals, this threshold 
shifts to lower glucose values after antecedent hypogly-
cemia (eg, in well-controlled type 1 diabetes)40–42 and to 
higher values in poorly controlled diabetes.43 This concerns 
in particular the nocturnal period, because sleep attenuates 
counterregulatory responses and shifts its elicitation to 
lower glucose concentrations,44,45 so that plasma glucose 
values around the 3.9 mmol/L cutoff can still be considered 
physiologic. Also, glucose values well below 3.9 mmol/L 
are needed for the appearance of hypoglycemic warning 
symptoms, even in people without diabetes.43,46,47 Finally, the 
allowed imprecision of current point-of-care glucose meters 
and continuous glucose monitors precludes detection of hypo-
glycemia with sufficient accuracy when this is based on a very 
narrow distinction between normo- and hypoglycemia.48 The 
clinical relevance of using the 3.9 mmol/L threshold value can 
be further questioned, when considering the treat-to-target 
algorithm that was used by the trials. Importantly, the close 
proximity of the 4.4 mmol/L lower bound of the treat-to-
target glucose range to the cutoff value may have amplified 
the number of “hypoglycemic” events, particularly during the 
night and in patients with the dawn phenomenon.49
The lower glucose-lowering potency of glargine-300 
compared to glargine-100 underlies another methodological 
concern. In all EDITION studies, instructions for the initia-
tion of insulin were based on prior insulin dose requirements 
or on body weight, which were similar for both glargine-300 
and glargine-100 study arms, despite the lower potency of 
the first. Thereafter, insulin dose adjustments were generally 
performed once weekly and restricted by protocol to increase 
by no more than 6 units. Consequently, it took longer for the 
patients randomized to the glargine-300 study arms to reach 
the glucose targets in the treat-to-target insulin regimens than 
for the patients randomized to the glargine-100 study arms. 
Such relative underdosing of glargine-300 as compared to 
glargine-100 may have contributed to the lower hypogly-
cemic event rates, especially since the threshold for the 
definition of hypoglycemia was set at such a relatively high 
glucose level (mentioned earlier). Indeed, the differences in 
hypoglycemic incidence between glargine-300 and glargine-
100 treatments were usually set during the first 8 weeks, 
when most of the dose titrations took place, particularly in 
the insulin-naïve population.
From a patient perspective, however, there are other 
potential benefits of glargine-300 over conventional glargine. 
Patients with profound insulin resistance who require very 
large doses of insulin may benefit from reduced injection 
site discomfort associated with the lower injection volume. 
A long-acting insulin with a longer half-life time suffers less 
from differences in timing of injection. Indeed, the product 
information leaflet of glargine-300 states that although the 
insulin is to be injected once daily, the time of administra-
tion may vary by 3 hours. A recent study demonstrated 
that increasing the insulin dosing range from 23–25 hours 
to 21–27 hours did not affect the efficacy and safety of 
glargine-300 in people with type 2 diabetes.50 More flex-
ibility of glargine-300 may particularly benefit shift workers 
or other patients with large variation in sleeping time and 
hours awake, and to some extent may benefit patients fre-
quently passing time zones. Another group likely to benefit 
(and who are usually excluded from clinical trials) are in- or 
outpatients who depend on nurses for the administration 
of insulin, particularly when the nurses have more tasks to 
perform and more patients to take care of. Finally, given the 
underlying mechanism of glargine, a more protracted release 
of insulin from the subcutaneous precipitates is expected to 
provide a more predictable glucose-lowering effect, resulting 
in less variation in glucose excursions. In daily practice, 
many patients complain about the poor reproducibility 
of the glucose-lowering effects of insulin, the variability 
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of which can be as high as 68% for NPH insulin, but has 
still been estimated at 48% for glargine-100.13 A recent 
study showed a pharmacodynamic variability of ~35% for 
glargine-300 in people with type 1 diabetes,51 which appears 
somewhat less than what has been previously reported for 
glargine-100.13 Better reproducibility may be welcomed 
by patients, as it allows both more accurate dose titration 
and may improve confidence in the ability to self-control 
diabetes management.
Areas of uncertainty
All clinical trials performed thus far were severely under-
powered to study the effect of glargine-300 on the risk of 
severe hypoglycemia. Examining patients at high risk of 
severe hypoglycemia, such as, those with impaired awareness 
of hypoglycemia, is eagerly awaited. An issue that remains 
to be resolved concerns the biochemical explanation for the 
observed longer duration of action of glargine-300 as com-
pared to glargine-100. Resolving this issue is important for 
two reasons. From a clinical perspective, it would allow for 
better understanding of the trial data on glucose-lowering 
efficacy and hypoglycemic risks in people with diabetes. On a 
more fundamental level, however, revealing the underlying 
mechanism may also reveal whether it would be valuable to 
aim for further dose concentration of glargine (or of other 
long-acting insulins). Glargine-300 will be marketed for 
the same price as conventional glargine. However, expen-
diture is expected to increase by 10%–20% due to its lower 
potency. A cost-effectiveness study is needed to assess the 
justification for such higher expected costs. Glargine-300 is 
not the only “new” long-acting insulin on the market. Insulin 
degludec was recently introduced to the market. This insulin 
analog has a half-life that is about twice that of glargine-100, 
which results in a flat and stable glucose-lowering effect after 
steady-state conditions have been reached.52 The develop-
ment of PEGylated insulin lispro, a long-acting insulin 
analog with hepatic preference and relatively lower peripheral 
hyperinsulinemia,53 has been recently stopped. Degludec has 
been reported to reduce the risk of nocturnal hypoglycemia in 
patients with both type 1 and type 2 diabetes, when compared 
to glargine-100,54 with recent analyses suggesting reductions 
in the risk of severe hypoglycemia in type 1 diabetes as well.55 
Which of these next-generation long-acting insulin ana-
logs perform better can only be satisfactorily answered by 
appropriately-sized head-to-head clinical trial comparisons. 
Such studies are underway and are urgently needed to provide 
guidance for clinicians as to which of these analogs fits best 
with individual patient requirements. Finally, future studies 
also need to address how well glargine-300 combines with 
newly developed glucose-lowering agents, including DPP-IV 
inhibitors, SGLT-2 inhibitors and, in particular, glucagon-like 
peptide-1 (GLP-1) receptor agonists. Indeed, adding GLP-1 
receptor agonists to a long-acting insulin analog, sometimes 
in a fixed combination, is extensively investigated for the 
treatment of type 2 diabetes,56,57 but to date no studies have 
been published on combinations with glargine-300.
Conclusion
Glargine-300 is a new formulation of glargine that con-
tains the same amount of insulin units in one-third of the 
volume of glargine-100. Glargine-300 has a prolonged and 
flatter pharmacokinetic and pharmacodynamic profile than 
glargine-100, allowing more flexibility for the timing of 
administration. Clinical studies suggest a lower risk of noc-
turnal hypoglycemia in people with insulin-requiring type 2 
diabetes, although it remains to be determined whether this 
effect sustains over longer periods of time. Paradoxically, 
patients with type 1 diabetes, although at much greater risk 
of hypoglycemia than people with type 2 diabetes, seem to 
derive less hypoglycemia-reducing benefit from switching to 
glargine-300. Further study is required to establish the place 
of glargine-300 in clinical practice in relation to existing and 
newly developed long-acting insulin formulations.
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